Advanced HNSCC tumors often contain mutations in the PI3K–AKT–mTOR pathway and respond strongly to KIs such as the selective mTOR-I Sapanisertib, which we assessed in our study [44,55]. This evidence concerns the gene PIK3CA and head and neck squamous cell carcinoma.